Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard Louis

Showing results (201-210 of 290) with videos related to

Pageof 29
Sort By:
Journal of Crohn'S & Colitis|January 10, 2023
ECCO Topical Review on Biological Treatment Cycles in Crohn's DiseaseNurulamin M Noor, Paula Sousa, Dominik Bettenworth, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|November 24, 2015
Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's DiseaseIsabelle Cleynen, Peter Konings, Caroline Robberecht, et al.
Journal of Crohn'S & Colitis|April 6, 2021
Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease FibrosisSophie Vieujean, Shurong Hu, Emeline Bequet, et al.
BMC Gastroenterology|March 28, 2024
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trialsLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Gut|August 12, 2024
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximabNicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Mucosal Immunology|October 20, 2019
Epithelial RABGEF1 deficiency promotes intestinal inflammation by dysregulating intrinsic MYD88-dependent innate signalingSophie El Abbas, Coraline Radermecker, Qiang Bai, et al.
Journal of Proteomics|May 19, 2024
Serum proteome signatures associated with ileal and colonic ulcers in Crohn's diseaseNicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Inflammatory Bowel Diseases|January 9, 2007
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitisFady Daniel, Marie-Anne Loriot, Philippe Seksik, et al.
Pageof 29

Showing results (201-210 of 290) with videos related to

Sort By:
Pageof 29
Journal of Crohn'S & Colitis|January 10, 2023
ECCO Topical Review on Biological Treatment Cycles in Crohn's DiseaseNurulamin M Noor, Paula Sousa, Dominik Bettenworth, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Inflammatory Bowel Diseases|November 24, 2015
Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's DiseaseIsabelle Cleynen, Peter Konings, Caroline Robberecht, et al.
Journal of Crohn'S & Colitis|April 6, 2021
Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease FibrosisSophie Vieujean, Shurong Hu, Emeline Bequet, et al.
BMC Gastroenterology|March 28, 2024
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trialsLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Gut|August 12, 2024
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximabNicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Mucosal Immunology|October 20, 2019
Epithelial RABGEF1 deficiency promotes intestinal inflammation by dysregulating intrinsic MYD88-dependent innate signalingSophie El Abbas, Coraline Radermecker, Qiang Bai, et al.
Journal of Proteomics|May 19, 2024
Serum proteome signatures associated with ileal and colonic ulcers in Crohn's diseaseNicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Inflammatory Bowel Diseases|January 9, 2007
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitisFady Daniel, Marie-Anne Loriot, Philippe Seksik, et al.
Pageof 29